SCYNEXIS Inc. Announces CFO Retirement; Appoints Sanjay Subramanian

What Happened

• SCYNEXIS filed an 8-K reporting that longtime CFO Ivor Macleod notified the company of his intent to retire and ceased serving as Chief Financial Officer, principal financial officer and principal accounting officer effective September 9, 2026; he will remain with the company through October 9, 2026 to support the transition.
• On September 10, 2026, SCYNEXIS announced that Sanjay Subramanian, age 50, has been appointed Chief Financial Officer (principal financial and accounting officer). Mr. Subramanian’s first date of employment was September 9, 2026. The company also issued a press release filed as Exhibit 99.1.

Key Details

• Compensation: annual base salary $500,000 and a one‑time sign‑on bonus of $20,000.
• Incentives: discretionary annual performance bonus up to 40% of base salary; stock option to purchase 100,000 shares, vesting over four years at an exercise price equal to the closing price on grant date.
• Severance: if terminated without “just cause” or he resigns for “good reason” (definitions in the agreement), severance is nine months base salary, nine months accelerated equity vesting and up to nine months COBRA; if within 12 months after a change of control, severance increases to 18 months base salary, full accelerated equity vesting and up to 18 months COBRA. Payments may be reduced to avoid adverse tax results.
• Background/No conflicts: Mr. Subramanian previously served as CFO at Inozyme and Ocugen and held finance roles at Aralez, Bausch Health, and General Motors. The filing states there are no arrangements, family relationships, or related‑party transactions requiring disclosure under Item 404(a).

Why It Matters

• Leadership change at the finance chief level can affect investor communications, financial planning and execution; SCYNEXIS has named an experienced biopharma finance executive with capital markets and M&A experience.
• The employment package (salary, bonus, equity and severance) ties the new CFO’s incentives to performance and retention, and provides protection in the event of a change of control—details investors may watch for when assessing dilution (option grant) and future guidance on expenses.
• The company filed a press release to announce the change, signaling a public transition plan and continuity steps (transition support through Oct 9).